In the context of liver disease, the NLRP3 inflammasome has been implicated in many studies as the primary activator of inflammation and initiates the development of NASH in both rodent models and humans [26,31,32,33]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.